News

FDA fully approves Pfizer vaccine – What it means for global rollout:

Published

4 years ago

August 24, 2021

Pfizer has received full approval for its COVID-19 jab, boosting confidence in the jab, worldwide

The U.S. Food and Drug Administration approved the first COVID-19 vaccine on Tuesday, which will now see the jab marketed as Comirnaty.

The vaccine has been available under emergency authorisation from the FDA for the prevention of COVID-19 disease in individuals 16 years of age and older.

In a statement from the FDA, the organisation says the vaccine also continues to be available under emergency use authorisation known as EUA, including for individuals 12 through 15 years of age.

EUA will also continue for the administration of a third dose in some immunocompromised individuals.

Today, FDA approved the first COVID-19 vaccine for the prevention of #COVID19 disease in individuals 16 years of age and older. https://t.co/iOqsxXV1fj
— U.S. FDA (@US_FDA) August 23, 2021

“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,”
Acting FDA Commissioner Janet Woodcock, M.D

“Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”

Since December 11, 2020, the Pfizer vaccination has been available under EUA in individuals 16 years of age and older.

That EUA authorisation was expanded to include those 12 through 15 years of age on May 10, 2021.

If you haven’t gotten vaccinated, please do it now. It could save your life and the lives of those you love. pic.twitter.com/ki39QS4PUx
— President Biden (@POTUS) August 23, 2021

EUA explained by the FDA:

EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products.

News

AI stocks surge amid market shifts and spending warnings

AI sector drives economic growth; Meta adjusts strategy, Palantir’s valuation sparks questions, and Nvidia leads amid rising competition.

Published

2 days ago

December 19, 2025

Harvey Vargas

AI sector drives economic growth; Meta adjusts strategy, Palantir’s valuation sparks questions, and Nvidia leads amid rising competition.

The artificial intelligence sector continues to be a major driver of growth for both the U.S. and global economies. Companies at the forefront of AI innovation are influencing market trends and reshaping industries worldwide.

Meta’s stock has rebounded slightly following reports of potential cost-cutting measures and job reductions in its Reality Labs division. Investors are watching closely as the company adjusts its strategy to manage rising expenses and optimize innovation.

Palantir is trading at over 120 times forward sales and 180 times forward earnings, signaling investor confidence but also raising questions about valuation risks. Meanwhile, Nvidia maintains a market cap of $4.2 trillion as a leading AI chip supplier, yet competition is ramping up.

These moves highlight the growing tension between tech giants’ AI ambitions and the practical need to balance profits with heavy R&D spending.

Some analysts, however, warn that rapid growth may not be sustainable, with current levels of AI-related spending potentially overshooting realistic returns.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@weareticker

#AIStocks #TechInvesting #Nvidia #Meta #Palantir #ArtificialIntelligence #StockMarket #TickerNews

News

AI investments set to surge in 2026 as companies target productivity gains

Analysts forecast $500 billion AI investment by 2026, transforming corporate spending priorities and enhancing economic productivity.

Published

2 days ago

December 19, 2025

Harvey Vargas

Analysts forecast $500 billion AI investment by 2026, transforming corporate spending priorities and enhancing economic productivity.

Analysts predict that artificial intelligence companies could invest over $500 billion in 2026, signaling a major shift in corporate spending priorities. This surge in capital allocation comes as businesses look to harness AI to drive growth and efficiency across multiple sectors.

Following strong third-quarter earnings, overall capital spending estimates for 2026 have been revised upward. However, investors are becoming more selective, focusing on companies that can clearly demonstrate revenue benefits from their AI investments, separating hype from tangible results.

AI adoption is expected to boost economic productivity, with significant investment already flowing into AI infrastructure such as semiconductors and data centres. The coming year could redefine how companies leverage technology to gain a competitive edge.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@weareticker

#AIInvestment #TechGrowth #FutureEconomy #DataCenters #Semiconductors #ArtificialIntelligence #ProductivityBoost #CapitalSpending

News

Stocks, AI and the economy: What to expect in 2026

2025’s market turmoil analyzed: AI hype, tariffs, global politics, and Federal Reserve impacts—tune in for expert insights!

Published

2 days ago

December 19, 2025

Harvey Vargas

2025’s market turmoil analyzed: AI hype, tariffs, global politics, and Federal Reserve impacts—tune in for expert insights!

2025 has been a rollercoaster for investors, with AI hype, tariffs, and global politics shaking up markets. We break down what these trends mean for your portfolio and the risks ahead.

Joining us for insights is Kyle Rodda from Capital.com, who explains how Treasury yields, unemployment data, and inflation readings are shaping investor sentiment. We also dive into what the Federal Reserve’s recent moves could mean for 2026.

From the potential impact of a 43-day government shutdown to payroll numbers and market expectations, this episode gives you the clarity you need to navigate the next year in stocks.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@weareticker

#StockMarket #Investing2026 #AIStocks #FederalReserve #EconomyWatch #MarketTrends #FinanceNews #TreasuryYields